Ticagrelor with ezetimibe in preventing MAC events after PCI in elderly patients with acute myocardial infarction

Objective To study the efficacy of Ticagrelor and ezetimibe in the treatment of elderly patients with acute ST-elevation myocardial infarction (STEMI) and the value of preventing major adverse cardiovascular events (MACE) after the patients undergoing percutaneous coronary intervention (PCI). Methods A total of 120 elderly STEMI patients receiving PCI in the First Peoples Hospital of Foshan from January 2016 to January 2021 were selected and were randomly divided into observation group and control group (n=60, each). Based on the conventional treatment in both groups, ticagrelor was used in control group, and ezetimibe with ticagrelor was given in observation group. MACE and adverse reactions were collected after PCI, levels of Interleukin（IL）-6, procalcitonin (PCT) and high-sensitivity C-reactive protein (hs-CRP) were detected, and left ventricular end diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF) were measured. Results Before operation, TIMI myocardial perfusion grade(TMPG) of pa